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a  b  s  t  r  a  c  t
Hepatitis  C  virus  (HCV)  infected  patients  are  known  to  be  at risk  of developing  liver complications  i.e.
cirrhosis  and liver  cancer.  However,  the  risks  of  morbidity  and  mortality  are  underestimated  because
they  do  not  take  into  account  non-liver  consequences  of chronic  hepatitis  C  virus  infection.  Numerous
extrahepatic  manifestations  have  been  reported  in  up to  74% of  patients,  from  perceived  to disabling  con-
ditions.  The  majority  of  data  concern  hepatitis  C virus-related  autoimmune  and/or  lymphoproliferative
disorders,  from  mixed  cryoglobulinaemia  vasculitis  to frank lymphomas.  More  recently, other  hepatitis
C  virus-associated  disorders  have  been  reported  including  cardiovascular,  renal,  metabolic,  and  central
nervous  system  diseases.  This  review  aims  to  outline  most  of the  extrahepatic  manifestations  that  are  cur-
rently  being  investigated,  including  some  of  autoimmune  and/or  lymphoproliferative  nature,  and  others
in  which  the  role  of  immune  mechanisms  appears  less  clear.
Beyond the  liver,  hepatitis  C  virus  chronic  infection  should  be  analyzed  as  a multifaceted  systemic  dis-
ease  leading  to  heavy  direct  and  indirect  costs.  The  accurate  consideration  of  extrahepatic  consequences
of  such  a  systemic  infection  signiﬁcantly  increases  the weight  of its pathological  burden.  The need  for
effective  viral  eradication  measures  is underlined.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by  Elsevier Ltd.
Open access under CC BY-NC-ND license.. Introduction
Hepatitis C virus (HCV) infection is a major health problem.
he World Health Organization (WHO) estimates that at least
50–170 million people, approximately 3% of the world’s pop-
lation, are chronically infected. These patients are known to
e at risk of developing liver complications, i.e., cirrhosis and
iver cancer, with an estimated liver-related mortality of 350,000
eople/year. However, the risks of morbidity and mortality are
nderestimated because they do not take into account the extra-
epatic consequences of HCV infection. Numerous extrahepatic
anifestations (HCV-EHMs) have been reported. In some large
ohort studies, up to 74% of patients experienced HCV-EHMs
f different severity, from perceived to disabling conditions [1].
∗ Corresponding author at: Department of Internal Medicine and Clinical
mmunology,  Hôpital La Pitié-Salpêtrière, 47-83, Boulevard de l’Hôpital, 75651 Paris
edex 13, France. Tel.: +33 01 42 17 80 27; fax: +33 01 42 17 80 33.
E-mail  address: patrice.cacoub@psl.aphp.fr (P. Cacoub).
ttp://dx.doi.org/10.1016/j.dld.2014.10.005
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. OpSome of these conditions are well documented and more com-
mon, while others are infrequent or their association with HCV
has not yet been proven [2–4]. Table 1 shows a tentative clas-
siﬁcation of HCV-EHMs according to scientiﬁc strength of the
association.
The majority of available data concern HCV-related autoim-
mune and/or lymphoproliferative disorders, from benign mixed
cryoglobulinaemia to frank lymphomas, which agrees with HCV
lymphotropisms [5]. More recently, other HCV-associated disor-
ders have been reported including cardiovascular, renal, metabolic,
and central nervous system diseases. This review aims to outline
most of HCV-EHMs that are currently being investigated in depth,
including some of autoimmune and/or lymphoproliferative nature,
and others for which the role of immune mechanisms appears
less clear. HCV disease appears as a major, mainly hidden, pub-
lic health problem leading to heavy direct and indirect costs. The
possibility that HCV infection can now be eradicated following
new antiviral therapies is important from a therapeutic and pre-
ventive point of view, for liver and non-liver consequences of the
disease.
en access under CC BY-NC-ND license.
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Table 1
Main  extra hepatic manifestations of hepatitis C Virus infection: tentative classiﬁ-
cation according to the strength of the association.
A. Signiﬁcant prevalence, consistent pathogenetic data and
“ex-adjuvantibus” criteria
Mixed  cryoglobulinaemia/cryoglobulinaemic vasculitis
B-cell  NHL
B.  Higher prevalence than controls
Type 2 diabetes mellitus type 2
Insulin resistance
Glomerulonephritis
Renal  insufﬁciency
Fatigue
Cognitive impairment
Depression
Impaired  quality of life
Cardiovascular  disorders (i.e. stroke, ischemic heart disease)
Sicca  syndrome
Arthralgia/myalgia
Auto-antibody production (i.e. cryoglobulins, rheumatoid factor, and
antinuclear, anticardiolipin, anti-thyroid and anti-smooth muscle
antibodies)
Monoclonal gammopathies
Immune  thrombocytopenia
Porphyria cutanea tarda
Lichen  planus
C.  Possible association
Polyarthritis
Pruritus
Fibromyalgia
Chronic  polyradiculoneuropathy
Lung  alveolitis
D.  Anecdotal association
Polymyositis
Dermatomyositis
Polyarteritis  nodosa
Psoriasis
Mooren  corneal ulcer
Erythema  nodosum
E.  Association with antiviral treatment (interferon alpha)
Hypo-hyperthyroidism
Depression
Fatigue
Impaired  quality of life
Sarcoidosis
Lichen
Skin  vasculitis
Peripheral neuropathy
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lHL, non-Hodgkin’s lymphoma; SS, Sjögren’s syndrome; PM/DM, polymyosi-
is/dermatomyositis; PAN, polyarteritis nodosa.
. Immune-related extrahepatic manifestations
.1. Cryoglobulinaemia vasculitis
Mixed cryoglobulinaemia (MC) vasculitis is a small vessel vas-
ulitis involving mainly the skin, the joints, the peripheral nerve
ystem and the kidneys. HCV infection represents the cause of
C in roughly 80% of cases. The disease expression is variable,
anging from mild symptoms (purpura, arthralgia) to fulminant
ife-threatening complications (glomerulonephritis, widespread
asculitis). Skin is the most frequently involved target organ. The
ain symptom is a palpable purpura, but chronic cutaneous ulcers
ay occur. Raynaud’s phenomenon and acrocyanosis, which may
volve to digital ulcerations, can also occur. Neurologic mani-
estations range from pure sensory axonopathy to mononeuritis
ultiplex. The most frequently described form is a distal sensory
r sensory-motor polyneuropathy, usually presenting with painful,
symmetric paresthesia which later become symmetric. Less fre-
uently, multiple mononeuropathy may  occur. Renal involvement
s an acute or chronic type-I membranoproliferative glomeru-
onephritis with sub-endothelial deposits. It represents 70–80% ofDisease 46 (2014) S165–S173
cryoglobulinaemia renal diseases and is strongly associated with
the type II IgM kappa MC.  The most frequent presentation is pro-
teinuria with microscopic haematuria and a variable degree of renal
insufﬁciency.
Cryoglobulinaemia is conﬁrmed by the detection of protein
precipitates in the patient’s serum maintained at 4 ◦C during at
least 7 days, which dissolve when heated at 37 ◦C. During chronic
HCV infection, MC  are immunochemically characterized as type
II or type III cryoglobulins, which consist of polyclonal IgG with
monoclonal or polyclonal IgM with rheumatoid factor (RF) activity,
respectively [6]. During follow-up, biological improvement can be
assessed by the quantiﬁcation of cryoglobulinaemia and other sur-
rogate markers (C4, CH50, RF). However, cryoglobulinaemia may
persist despite clinical response of vasculitis under therapy.
During  HCV infection, cryoglobulinaemic vasculitis is associ-
ated with advanced age, longer duration of infection, type II MC,
a higher MC  serum level and clonal B-cell expansions in both
the blood and liver. The worse prognostic factors are age over 60
yrs at diagnosis and renal involvement. The overall 5 year sur-
vival rate after the diagnosis of vasculitis ranges from 90% to 50%
in case of renal involvement. Even in the absence of signiﬁcant
renal failure, increased mortality from liver involvement, cardio-
vascular disease, infection and lymphoma has been reported [7].
In a recent retrospective Italian study of 231 patients, 79 of 97
deaths were linked to vasculitis (46%, of whom one-third due to
renal involvement), cancer or haemopathy (23%), or liver disease
(13%) [8]. Life-threatening MC  complications are observed in up
to 10% of the patients, with a mortality of almost two-thirds [9].
HCV-related cryoglobulinaemia may  result in progressive (renal
involvement) or acute (pulmonary haemorrhage, gastrointestinal
ischaemia, cardiac, CNS involvement) life-threatening organ dam-
age. The mortality rate of these manifestations ranges between 20%
and 80% [10,11]. Intestinal ischaemia, pulmonary haemorrhage,
high cryocrit levels and type II MC are associated with severe prog-
nosis [9].
There are multiple factors predisposing HCV-infected patients
to develop cryoglobulinaemic vasculitis. Interaction between HCV
and lymphocytes directly modulates B- and T-cell function and
results in polyclonal activation and expansion of B-cell produc-
ing IgM with RF activity [12]. CD4+CD25+FoxP3+regulatory T cells,
which have been shown to control autoimmunity, are signiﬁ-
cantly reduced in HCV-MC vasculitis patients [13,14]. This defect
in immune regulation may  account for the expansion of periph-
eral auto-reactive B-cells that drive MC  vasculitis. The HLA type
II polymorphism may  predispose to HCV-MC. HLA-DR11 is associ-
ated with MC  vasculitis whereas HLA-DR7 appears to protect from
type II MC  [15]. In a recent multi-centre genome-wide association
study performed in 356 HCV-MC patients and 447 HCV-positive
controls, signiﬁcant associations were identiﬁed on chromosome 6,
a  SNP (Single Nucleotide Polymorphism) located within an intronic
region of NOTCH4 (p = 6.2 × 10−9) and another found between HLA-
DRB1 and HLA-DQA1 (p = 1.2 × 10−7) [16]. It has been shown that
a higher percentage of a particular allele of the promoter of the
B-cell activating factor (BAFF) – known to be related to higher
translational activity of the gene [17] – and different expression
patterns on circulating lymphocytes of microRNAs are involved
in lymphoproliferative and/or autoimmune disorders [18]. In con-
trast, speciﬁc virological factors have not yet been identiﬁed.
HCV-induced vasculitis manifestations and MC respond to clear-
ance of HCV during combination antiviral therapy with pegylated
interferon (PEG-IFN) plus ribavirin [19,20]. Patients who  relapse
for HCV infection, after responding to antiviral therapy, usually
relapse for vasculitis with the return of viraemia [21]. In case of
persistent MC,  relapse of vasculitis may  also occur in a few patients
despite achieving a sustained virologic response (SVR). In such
patients, a different underlying condition should be considered,
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specially B-cell lymphoma [22]. Recent use of triple anti-HCV
herapy with PEG-IFN/ribavirin and a speciﬁcally targeted antivi-
al agent has led to improved SVR rates. In an open label French
rospective single-centre cohort study [23], the safety and efﬁ-
acy of combination therapy with PEG-IFN/ribavirin plus a NS3/4A
rotease inhibitor (boceprevir or telaprevir) was  evaluated in 30
atients with HCV genotype 1 (GT1) infection and MC vasculi-
is. At week 72, twenty (66.7%) patients were complete clinical
nd sustained virological responders (SVR). Serious adverse events
ccurred in 14 (46.6%) patients. The baseline factors associated with
erious adverse events included liver ﬁbrosis (p = 0.045) and a low
latelet count (p = 0.021). In another prospective, controlled, single-
entre Italian cohort study [24], 35 HCV GT1 patients received
EG-IFN/ribavirin for 48 weeks in combination with boceprevir,
fter a four-week period of PEG-IFN/ribavirin. Patients showed a
rastic reduction of cryocrit values, and an improvement in MC
ymptoms. When compared with matched HCV controls with-
ut MC,  SVR was less frequent in MC  patients (23.9% vs. 70%;
 = 0.01). Other direct-acting antivirals are now becoming available.
he NS3/4A inhibitor Simeprevir and NS5B inhibitor Sofosbuvir
ave recently been licensed. These agents facilitate the use of
hortened courses of combination IFN-free therapy, which are asso-
iated with high (>95%) SVR rates and relatively little toxicities.
nternational guidelines (i.e., EASL 2014) [25] state that treatment
hould not be deferred in patients with signiﬁcant liver ﬁbrosis and
ith clinically signiﬁcant extra-hepatic manifestations, like symp-
omatic cryoglobulinaemia. As SVR has been previously associated
ith MC  vasculitis remission in most patients, there is no doubt
hat the new HCV treatments will be a major beneﬁt for these
atients.
Rituximab is also an interesting therapy in MC,  as it targets
-cells, which are responsible for cryoglobulin production and
nally vasculitis lesions [26–30]. A randomized controlled trial in
7 patients with MC  vasculitis showed that rituximab has a better
fﬁcacy than conventional treatments (i.e., glucocorticoids, aza-
hioprine or cyclophosphamide, or plasmapheresis) [31]. Similar
esults have been reported in a placebo controlled trial [32]. The
se of rituximab was shown to be safe in HCV patients, in con-
rast to HBV infected patients [33]. A prospective study in patients
ith HCV-related MC  and advanced liver disease showed that ritux-
mab was safe and associated with clinical improvement of the liver
isease [34]. Two controlled clinical trials demonstrated that ritux-
mab plus PEG-IFN/ribavirin compared to PEG-IFN/ribavirin led to
linical remission faster with better renal response rate, and higher
ates of cryoglobulin clearance [35,36].
To summarize, patients with mild to moderate HCV-related MC
asculitis should receive optimal antiviral treatment. In patients
ith severe vasculitis (i.e. worsening of renal function, mononeu-
itis multiplex, extensive skin disease, intestinal ischaemia etc.)
ontrol of disease with rituximab, with or without plasmaphere-
is, is usually required before initiation of antiviral therapy [37].
areful monitoring for adverse effects is mandatory, since some
anifestations of HCV-MC, such as peripheral neuropathy or skin
lcers, may  worsen with IFN-based therapy. Room for other treat-
ent strategies is very limited. Low-dose corticosteroids may  help
o control minor intermittent inﬂammatory signs such arthralgia
ut are unsuccessful in case of major organ involvement. Other
mmunosuppressants should be given only in case of refractory
orms of HCV-MC, frequently associated with underlying B-cell
ymphoma [38].
.2.  B-cell lymphoproliferative diseasesThe strong correlation between HCV infection and MC,  a benign
ut prelymphomatous condition, leads to the hypothesis that HCV
ay  be involved in the pathogenesis of other lymphoproliferativeDisease 46 (2014) S165–S173 S167
diseases (LPDs). A high prevalence of HCV infection in patients
with B-cell non-Hodgkin’s lymphoma (B-NHL) was ﬁrst reported
in limited cohorts [39,40]. During the last two  decades, the asso-
ciation between HCV and several hematologic malignancies, most
notably B-NHL, was  conﬁrmed [41,42] with a gradient from north
to south. Meta-analyses conﬁrmed an increased risk of lymphoma
in HCV subjects, with varying degrees of risk [41,43–46]. HCV was
associated with marginal zone NHL (OR 2.47), diffuse large B-cell
NHL (DLBCL) (OR 2.24) and LPL (OR 2.57). A serum monoclonal
gammopathy (MG), more frequently IgMk, diagnosed as MG  of
uncertain signiﬁcance, was frequently observed in HCV patients
[47].
A lower cumulative incidence of lymphoma development in
patients who eradicated the virus conﬁrms this association and
suggests that HCV treatment could be a preventive measure [48].
SVR induced NHL regression while a viral relapse was followed
by lymphoma recurrence [49,50]. In the study by Hermine et al.,
HCV-positive splenic lymphoma with villous lymphocytes (SLVL)
regressed after anti-viral therapy (AT) [51]. These data agree with
the regression of expanded B-cell clones following successful AT
with the new expansion of the same clones in relapsers [52,53].
This regression was also shown in patients with benign conditions
(i.e., type II or III MC), whereas a persistent B cell clone, despite
a clinical remission, was evidenced in SVRs with SLVL [50]. This
suggests the presence of no-return points in the HCV-driven lym-
phoma genesis leading the process progressively less dependent
from the etiologic agent [54].
HCV-related LPDs are the result of multiple and cooperating
events. A pivotal role seems to be played by a sustained activa-
tion of B-cells, an inhibition of B-cell apoptosis, genetic/epigenetic
and environmental factors [54,55]. Arguments in favour of a sus-
tained antigenic stimulation include the HCV lymphotropism and
the detection of HCV antigens in peripheral blood, or liver inﬁl-
trating lymphocytes and lymph nodes [56–58]. Special emphasis
was dedicated to the binding between the surface E2 protein and
the tetraspanin CD81 leading to a lower B-cell activation threshold
[59]. The analysis of BCR sequence and afﬁnity in HCV NHL showed
conﬂicting results [60,61]. The lymphotropism agrees with a higher
HCV infection prevalence in peripheral blood mononuclear cells
(PBMCs) and bone marrow [62,63] and was conﬁrmed by in vivo
and in vitro studies [64,65]. HCV-infected cells showed an increased
rate of mutations of oncogenes and Ig genes [66]. Transgenic mod-
els showed a correlation between the expression of HCV core and
lymphoma [67,68]. The (14;18) translocation causes increased Bcl-
2 levels and abnormal B-cell survival [53,69,70] and disappears
after AT [52,71,72]. The role of cytokines and chemokines has also
been studied [12,73–76], with a special attention to the B-cell acti-
vating factor (BAFF) [55,77,78]; [17,79]. More recently, the role of
microRNAs seems critical in the pathogenesis of HCV-related LPDs
[18,80].
Treatment of HCV-positive lymphoma with AT has a double
aim: the eradication of the etiologic factor and the reversion of
lymphoma genic mechanisms. Several studies showed a clinical
remission following AT in low-grade B-cell NHL, mainly in MZL
(SMZ, SLVL) [50,51,81–84]. A retrospective study evaluating the
effect of IFN-based AT in 134 patients with indolent HCV-associated
NHL showed that the use of AT at any time is associated with
an improved overall survival [84]. In patients with aggressive
lymphomas, the use of IFN-based AT is generally inappropriate,
due to IFN haematological toxicity. However, the use of AT fol-
lowing NHL remission showed improved clinical outcome and
prolonged disease free survival [85,86]. The use of rituximab in
HCV-associated NHL - in monotherapy or in combination with AT
and/or chemotherapy - appears interesting, especially in low-grade
NHL [36,87]. The availability of direct acting antivirals with a high
virological efﬁcacy (SVR > 90%) and without haematological toxicity
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ill hopefully allow the combination of new AT with chemother-
py, taking into account possible drug-drug interactions.
.3. Arthralgia/myalgia
Arthralgia is reported in 40–80% of HCV-infected patients with
C [2,88]. Joint pains are bilateral, symmetric, non-deforming and
nvolve mainly knees and hands, more rarely elbows and ankles.
CV arthritis, unrelated to MC,  is less common (less than 10% of
atients). Rheumatoid Factor (RF) activity is found in 70-80% of
C patients but is not correlated with the presence of joint dis-
ase. There is no evidence of joint destruction. Antibodies to cyclic
itrullinated peptides are absent. Some treatment modalities for
CV infection, including IFN, may  aggravate arthralgia and myalgia,
hus confounding clinical presentation. It is imperative to deter-
ine whether symptoms such as arthralgia, myalgia, and arthritis
ccur in patients with HCV infection due to primary chronic HCV
nfection or to a newly developed rheumatologic disease.
.4.  Sicca syndrome
Sicca  symptoms in either the eyes or mouth have been reported
n 20% to 30% of HCV infected patients, whereas less than 5% of
atients with a deﬁned Sjögren’s syndrome are HCV-positive [2].
any similarities exist between HCV-related Sicca syndrome and
true” Sjögren’s syndrome [89], however, a characterized Sjögren’s
yndrome (deﬁned by the presence of xerostomia, xerophthalmia,
nti-SSA or anti-SSB antibodies and typical salivary gland histology)
s rarely found in HCV patients. HCV-positive Sjögren’s syndrome
atients are older and more likely to have photosensitivity and
ryoglobulinaemia than patients with primary Sjögren’s syndrome.
lthough low titres of antinuclear antibodies and RF are common
n patients with HCV-related Sicca syndrome, the presence of Sjö-
ren’s syndrome-related autoantibodies (anti-SSA/SSB antibody) is
ncommon. HCV may  induce sialadenitis by itssialotropism [90].
he expression of the HCV E1 and E2 glycoproteins in trans-
enic mice is associated with the development of sialadenitis
91].
.5. Auto-antibodies
The prevalence of circulating autoantibodies is high in patients
ith chronic HCV infection [1,2]. The most frequent immuno-
ogic abnormalities include mixed cryoglobulins (60–90%), RF
ctivity (70%), and antinuclear (20–40%), anticardiolipin (15%),
nti-thyroid (12%) and anti-smooth muscle antibodies (7%). At least
ne immunologic abnormality is present in up to 53% of HCV
atients. These autoantibodies are not associated with manifesta-
ions of a connective tissue disease except for mixed cryoglobulins.
 possible reason for antibody production is again the HCV-induced
veractivation and proliferation of B lymphocytes.
. Other extrahepatic manifestations
.1. Increased non liver-related mortality/morbidity
Most studies have found liver disease to be the primary cause
f mortality in HCV infected patients [92–98]. HCV infection also
howed a higher mortality rate for extra-hepatic complications (i.e.,
ardiovascular, renal, tumoural) [96,97,99,100].
The study by Lee and colleagues attributed to serum HCV
NA positivity a signiﬁcantly higher mortality risk from non-liver-
elated causes [96]. All-cause mortality in HCV subjects was twice
hat in HCV-negative subjects [93]. Some studies did not ﬁnd sig-
iﬁcant differences in overall mortality rates between patients
ith and without HCV infection [101]. It appears important toDisease 46 (2014) S165–S173
compare  patients with persisting HCV infection to those that
cleared the virus after therapy (“ex adjuvantibus” criterium). Viral
eradication signiﬁcantly reduced the rate of extra-hepatic deaths
[48,92,95,102]. Backus et al. describe a large population of HCV
infected patients (12,166 GT1 with SVR rates of 35%; 2904 GT2 with
SVR rates of 72%; 1794 GT3 with SVR rates of 62%) [92]. After a
median follow-up of 3.8 years, SVR was associated with improved
survival among patients with HCV genotype 1, 2, and 3 with sub-
stantial comorbidities. These ﬁndings extend previous observations
that SVR reduced liver related mortality was  associated with an
all-cause mortality reduction.
3.2.  Cardiovascular diseases
It  has been suggested that several types of chronic infections –
including HCV – can trigger cardiovascular diseases and be deﬁned
as risk factors for these [103–105]. Since chronic infections may
be curable, their identiﬁcation as causal contributors to cardiovas-
cular risk could offer new perspectives in cardiovascular disease
prevention.
Initial Asian studies have suggested the association between
HCV seropositivity and an increased risk of carotid-artery plaques
and carotid intima-media thickening, independently of other clas-
sical risk factors for atherosclerosis [103–106]. Two  Italian cohort
studies suggested an association with carotid atherosclerotic
lesions in Europe too, with a possible local direct role of the virus in
initiating the plaque [107–109]. A review of the literature showed
that HCV infected subjects have a higher likelihood of developing
carotid atherosclerotic plaques compared to HCV negative con-
trols [110]. Carotid atherosclerosis risk in HCV patients was mostly
evident in case of active viral replication and in some geographic
areas [103,108]. The observation that the virus induces the pro-
duction of pro-atherogenic cytokines [102] and the link between
chronic HCV infection and the plaque instability, support a role of
the virus in increasing the risk of cerebrovascular diseases [111].
More recent studies performed in HCV mono-infected or HCV-HIV
co-infected patients conﬁrmed the link between HCV infection and
carotid atherosclerosis [109,112,113]. He et al. showed a signif-
icantly increased risk of stroke in 22,171 HCV infected subjects
compared to 87,418 controls [114]. Retrospective cohort studies
have suggested a beneﬁcial effect of AT on the incidence of stroke
in HCV infected patients [115]. A study conducted in three groups of
diabetics followed for 8 years, showed a decreased cumulative inci-
dence of ischaemic stroke in treated vs. non-treated HCV patients
[95].
HCV infection was shown to play a role in the risk of coronary
artery disease, after adjustment for classical cardiovascular risk
factors [116]. Lee et al. [96] analyzed the causes of mortality in a
large cohort of HCV patients, anti-HCV positive/HCV RNA negative
and anti-HCV positive/HCV RNA positive. A long follow-up period
showed that anti-HCV positive patients had higher mortality rates
from cardiovascular diseases (HR 1.50; 95% CI 1.10–2.03). Subjects
with positive viraemia showed higher death rates, while HCV RNA
negative patients had rates similar to the control group. In a Tai-
wanese study, 1411 HCV subjects with diabetes mellitus treated
with AT (PEG-IFN plus RBV) were matched with 1411 HCV-positive
diabetic patients not treated with AT and with 5644 HCV-negative
diabetic patients [95]. After an 8-year median follow-up, the cumu-
lative incidence of death signiﬁcantly decreased from untreated to
treated (23.6% vs. 13.0%). The incidences of end-stage renal disease,cohort of treated vs. untreated patients. Maruyama et al. showed an
improvement in the myocardial perfusion defect in patients with
SVR, but a worsening in relapsers, after a transient improvement
concomitant with viraemia negativation [117].
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.3. Renal insufﬁciency
Type  I membrano-proliferative glomerulonephritis (MPGN)
ssociated with MC  is the most common form of kidney dis-
ase associated with HCV infection. Less frequently described
esions are membrano-proliferative glomerulonephritis without
ryoglobulinaemia, membranous nephropathy, and mesangiopro-
iferative glomerulonephritis. Occasional cases of focal segmental
lomerulosclerosis, ﬁbrillary or immunotactoid glomerulopathies,
hrombotic microangiopathy have been reported.
The most frequent (70–80%) renal clinical and histological pic-
ure in HCV-MC vasculitis is that of acute or chronic type-I MPGN
ith sub-endothelial deposits, which is strongly associated with
he type II IgM cryoglobulinaemia [118]. The most frequent pre-
entation (55%) is proteinuria with microscopic haematuria and
 variable degree of renal insufﬁciency. Acute nephrotic (20%)
r nephritic syndrome (25%) can also reveal MC  renal involve-
ent. New onset arterial hypertension is seen in 80% of cases.
arly serum complement component (C1q, C4) are very low.
hronic renal insufﬁciency may  develop in 10–20% of HCV-MC
atients after follow-up of a decade or more. Morphological fea-
ures are characterized by important monocyte inﬁltrates with
ouble contours of the basement membrane, large, eosinophilic
nd amorphous intra-luminal thrombi. In indirect immunoﬂuo-
escence, intra-glomerular sub-endothelial deposits of IgG, IgM
nd complement components are observed. The electron micro-
copic features with sub-endothelial and intra-luminal deposits
resenting a crystalloid aspect are pathognomonic. Vasculitis
f small renal arteries or extra-capillary crescents are rarely
bserved.
Several authors have found evidence of the association between
CV and other glomerular disease in both native [119] and trans-
lanted kidneys [120]. A large case-control study, carried out
mong U.S. male veterans hospitalized between 1992 and 1999
121], identiﬁed 34,204 patients who were hospitalized with HCV
cases) and 136,816 randomly selected patients without HCV (con-
rols). There was a greater proportion of MPGN among patients with
CV (0.36% vs. 0.05%, p < 0.0001), but not membranous glomeru-
opathy (0.33% vs. 0.19%, p = 0.86). HCV infection was  associated
ith a 40% higher prevalence of renal insufﬁciency (serum cre-
tinine ≥ 1.5 mg)  compared with people without HCV infection,
fter adjusting for age, gender, race, diabetes, and hypertension
122]. Some surveys extracted from large clinical databases have
uggested an impact of HCV on prevalence and incidence of kid-
ey disease in the general population [122–126]. HCV co-infection
as also linked with a signiﬁcant increase of the risk of HIV-
elated kidney disease [127,128]. A recent review suggests that
CV affects renal function in the general population [129]. In
ultivariate analysis, anti-HCV seropositive status was  associ-
ted with low GFR, with odds ratio up to 2.80. A signiﬁcant
ink between HCV and proteinuria has been reported in appar-
nt healthy individuals, with odds ratio ranging from 1.14 to
.99 [124,125,128,130,131].  Anti-HCV positivity was signiﬁcantly
ssociated with proteinuria, independently of common metabolic
actors, such as diabetes mellitus, arterial hypertension, obesity,
nd dyslipidemia. In a recent population-based cohort, among
,267,270 Taiwanese residents diagnosed with diabetes mellitus
95], three groups were analyzed, 1411 HCV infected patients who
eceived PEG-IFN plus ribavirin (treated cohort), 1411 HCV infected
ntreated controls and 5644 HCV-negative diabetic patients (unin-
ected cohort). The 8-year cumulative incidence of end stage renal
isease in the treated, untreated, and uninfected cohorts were
.1% (95% CI, 0.3–2.0%), 9.3% (5.9–12.7%), and 3.3% (2.3–4.3%),
espectively (p < 0.001). As compared with the untreated cohort,
T was associated with HR of 0.16 (0.07–0.33%) for end stage renal
isease.Disease 46 (2014) S165–S173 S169
The Kidney Disease Improving Global Outcomes (KDIGO) group
recommends that all patients with chronic kidney disease should
be tested for HCV [132]. Despite the lack of well-designed tri-
als, KDIGO also recommends that patients with acute ﬂares of MC
and MPGN be treated with IFN-based AT. Ribavirin dosage should
be closely monitored due to the risk of anaemia and should be
avoided altogether in patients with chronic kidney disease. There is
some evidence that the addition of rituximab may  be useful. HCV-
related MC  patients with kidney involvement showed greater renal
response rates when treated with a combination of rituximab and
PEG-IFN plus ribavirin compared with PEG-IFN and ribavirin alone
[35,36].
Recently, data has been gathered on the association between
HCV and glomerular disease in the liver [133,134] or kid-
ney/liver [135] transplanted population. The natural history of
these HCV-associated nephropathies is characterized by remission
and relapsing phases.
3.4.  Diabetes and insulin-resistance
Many  studies have evaluated the association between HCV
chronic infection, insulin-resistance (IR) and diabetes mellitus. The
abnormalities of the carbohydrate metabolism, including hyperin-
sulinaemia and IR, known to be “per se” related to hepatic diseases,
represented the rationale for research on this relationship.
Insulin-resistance is an often undetected condition, commonly
coexisting with obesity and metabolic syndrome, and possibly
evolving to type 2 diabetes. Taskoparan and colleagues, in a small
cohort of patients treated with anti-HCV therapy failed to estab-
lish a correlation between IR and chronic HCV infection [136]. The
presence of IR was  evaluated in patients achieving SVR after PEG-
IFN plus ribavirin AT in HCV mono-infected patients. On one hand,
the treatment response was not impaired by IR. On the other hand,
treatment failure and high body mass index were independent risk
factors for de novo appearance of IR after treatment. No new IR
cases were registered in SVR patients, suggesting that viral eradi-
cation in HCV patients could prevent IR onset and its evolution to
diabetes [137]. Insulin resistance has been shown to impair SVR
rate to PEG-IFN plus ribavirin in HIV-hepatitis C virus-coinfected
patients [138].
HCV-related type 2 diabetes mellitus may arise from a com-
plex interaction between IR, steatosis and inﬂammatory processes
[139]. Epidemiologic studies supporting the association between
type 2 diabetes and HCV infection were published in the early 1990s
[140–143]. Persistently mild to moderate transaminase elevation in
type 2 diabetes should be attributed to HCV infection rather than
to metabolic disturbances [144]. Larger epidemiologic studies were
also published [145,146]. The prevalence of diabetes was  higher in
HCV- than HBV-related cirrhosis (23.6% vs. 9.4%; OR 2.78; 95% CI,
1.6–4.79; p = 0.0002). Diabetes was associated with the presence of
a cirrhosis and male gender. In HCV core transgenic mice, the viral
protein seemed to induce increasing TNF alpha levels in the liver,
which in turn promoted the induction of IR [147]. The high levels of
TNF alpha inhibited the Insulin Substrate Receptor-1 (ISR-1) caus-
ing IR and its possible evolution to diabetes. In HCV core transgenic
mice, a decreased expression of ISR-1 and ISR-2 mediated by ubi-
quitination was  observed and inversely proportional to the ﬁbrosis
stage [148].
Few  studies have focused on type 1 diabetes and HCV and they
are also rather small [146,149,150]. The mechanism suggested for
this association was a molecular mimicry [151,152], as proposed for
other infections [153,154]. A very recent epidemiologic study con-
ducted in Egypt in a paediatric population of 150 diabetic patients
revealed a prevalence of HCV infection higher than in controls
[155].
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.5. Fatigue, depression, cognitive impairment and impaired
uality  of life (HRQoL)
Neurocognitive morbidity has been reported in individuals with
hronic HCV infection, and do not completely correlate with the
everity of liver disease [156,157]. Cognitive impairment may  be
xpressed in a wide variety of medical and psychiatric conditions
e.g., fatigue, depression, substance abuse). Short-term neuro-
sychiatric complications are not uncommon in individuals with
hronic HCV infection during treatment with IFN. The detection
f HCV genetic sequences in post-mortem brain tissue raises the
ossibility that the presence of HCV infection in the central ner-
ous system may  be related to the reported neuropsychological
ymptoms and cognitive impairment [158].
HRQoL of HCV patients is diminished compared with controls
159–161]. HCV infection, along with its treatment, leads to symp-
oms that compromise HRQoL [162]. HRQoL worsens with more
dvanced liver disease and therapy, leading to a reduction in
dherence [163,164]. Viral eradication correlates positively with
mprovements in HRQoL [159,165]. HRQoL has been studied in
atients who participated in sofosbuvir (SOF) clinical trials, includ-
ng IFN-free regimens [98]. Compared to placebo, the SOF and
ibavirin combination was  not associated with HRQoL impairment.
ompared to SOF and ribavirin, HRQoL was signiﬁcantly more
mpaired in the PEG-IFN and ribavirin arm. Anaemia and receiv-
ng IFN were predictors of HRQoL impairment during treatment.
chieving SVR after 12 weeks of follow-up with SOF and ribavirin
as associated with improvement in HRQoL. HCV has been associ-
ted with a decreased ability to function both at work and at home,
ith obvious cost implications. Poor HRQoL can also lead to difﬁ-
ulties with interpersonal relations, decreased feelings of self-value
nd utility, and depression. Based on the Short Form 36 (SF-36)
ealth Survey questionnaire, patients with HCV infection consis-
ently show deﬁcits in several domains, particularly those involving
heir physical role, general health and vitality, vs. healthy controls
162,166,167].
Depression has been documented in 28% of HCV patients using
he Structured Clinical Interview for DSM-IV Axis I Disorders [168].
he presence of depressive symptoms is a consistent predictor
f HRQoL during AT with PEG-IFN plus ribavirin [169]. HCV may
irectly affect the CNS through alterations in serotonergic and
opaminergic neurotransmission with resultant depressive symp-
oms [170]. This mechanism may  explain other central nervous
ystem symptoms seen in HCV infection, such as fatigue and cogni-
ive impairment [171–174]. Prior to starting AT including PEG-IFN,
ental health should be thoroughly assessed, as patients with a his-
ory of major depressive disorder are at greater risk of developing
epression during HCV treatment. Antidepressant or antianxiolytic
reatment may  be considered before initiating AT [175].
Cognitive impairment is well described in chronic HCV infection.
t is a common symptom in persons with end-stage liver disease
176]. In the HALT-C trial, 33% of 201 patients with advanced ﬁbro-
is who underwent neuropsychological testing had mild cognitive
mpairment on entering the trial [177]. Patients with chronic HCV
nfection who are free from co-morbid factors do have higher levels
f cognitive impairment than healthy controls [178]. HCV erad-
cation leads to improved cognitive function [179] and cerebral
etabolism [171]. SVRs (but not the non responders) demonstrated
igniﬁcant improvements in verbal learning, memory, and visuo-
patial memory.
Fatigue is one of the most frequent and disabling complaints
mong HCV patients (prevalence: 50–67%), and it independently
redicts poor HRQoL [180]. In a prospective study, during the
rst visit of 1614 HCV patients and 412 controls, fatigue was
resent in 53% of patients (95% CI: 51–56) vs. 1% of controls (95%
I: 0–2) [181]. In 17% of patients fatigue was severe, impairingDisease 46 (2014) S165–S173
activity. Fatigue was independently associated with female gender,
age over 50 years, cirrhosis, and depression. There was no signiﬁ-
cant association between fatigue and the following characteristics:
viral load or genotype, alcohol consumption, abnormal thyroid
function, and type and level of cryoglobulinaemia. Chronic fatigue is
associated with bad quality of sleep and increased nocturnal activ-
ity in HCV patients, suggesting an alteration of sleep architecture
behind fatigue in HCV-associated encephalopathy [182].
4.  Conclusion
Beyond the liver, HCV chronic infection leads to a multifaceted
systemic disease. Type and evolution of such extrahepatic man-
ifestations are difﬁcult to predict. The accurate consideration
of extrahepatic consequences of such a systemic infection sig-
niﬁcantly increases the weight of its pathological burden and,
consequently, the need for effective eradication measures.
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